Document 0585
 DOCN  M9460585
 TI    Transfusion therapy in sickle cell disease patients: methods and acute
       indications.
 DT    9404
 AU    Campbell LC; Von Burton G; Holcombe RF; Dept of Medicine, Louisiana
       State University School of; Medicine-Shreveport.
 SO    J La State Med Soc. 1993 Dec;145(12):515-21. Unique Identifier :
       AIDSLINE MED/94165557
 AB    Management of transfusion therapy in sickle cell disease patients with
       acute complications is often made difficult because of confusing
       indications, a variety of methods, disparate goals, and varying needs
       for maintenance transfusion. In priapism, acute chest syndrome, many
       major surgical procedures, toxemia of pregnancy, and cerebrovascular
       accidents, the target hemoglobin A level should be made as close to 100%
       as possible by mechanized red blood cell exchange. If mechanized
       exchange is unavailable, manual exchange should be instituted.
       Hemoglobin A should be maintained at greater than 60% to 70% by periodic
       simple transfusion until patients are fully recovered. Stroke patients
       should undergo maintenance transfusions for at least 3 years and perhaps
       5 to 12 years. Physicians and patients should be aware of the
       transfusion-related risks of hepatitis and HIV infection.
       Alloimmunization and iron overload should be minimized in patients
       requiring frequent transfusions and chelation therapy should be utilized
       for iron overload.
 DE    Anemia, Sickle Cell/COMPLICATIONS/*THERAPY  *Blood Transfusion/ADVERSE
       EFFECTS/METHODS  Human  Support, Non-U.S. Gov't  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).